文献速递产科母胎医学

1型糖尿病孕妇持续血糖监测与自我血糖监测的经济学分析

Continuous glucose monitoring vs. self-monitoring in pregnant individuals with type 1 diabetes: an economic analysis.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-06-21

本研究建立经济学分析模型,从卫生系统视角比较1型糖尿病孕妇持续血糖监测与自我血糖监测的总成本(2022年美元)。基础分析显示持续血糖监测每人成本26837美元,自我监测为29039美元,每人节省2202美元。蒙特卡洛模拟显示持续血糖监测在98.7%的模拟中为最优策略。

要点

  • 模型纳入妊娠期高血压疾病、大于胎龄儿、剖宫产、新生儿重症监护病房入住和新生儿低血糖。
  • 持续血糖监测每人成本26837美元,自我监测29039美元,每人节省2202美元。
  • 持续血糖监测在98.7%的蒙特卡洛模拟中为最优策略。

核心结论

  • 与自我监测相比,持续血糖监测对1型糖尿病孕妇是一种经济的策略。

研究设计与样本

  • 建立经济学分析模型,在1型糖尿病孕妇队列中比较持续血糖监测与自我监测两种血糖监测策略。
  • 模型考虑妊娠期高血压疾病、大于胎龄儿、剖宫产、新生儿重症监护病房入住和新生儿低血糖。
  • 主要结局为从卫生系统视角计算的每种策略的总成本(2022年美元),以自我监测为参照组。
  • 概率、相对风险和成本来自文献,成本调整为2022年美元,并通过1000次蒙特卡洛模拟检验稳健性。

主要发现

  • 基础分析中,持续血糖监测的妊娠成本为26837美元,自我监测为29039美元,每人成本降低2202美元。
  • 对增量成本影响最大的参数包括新生儿重症监护病房入住的相对风险、新生儿重症监护病房入住成本、持续血糖监测成本和常规照护成本。
  • 蒙特卡洛模拟显示持续血糖监测在98.7%的模拟中为最优策略。
  • 单因素敏感性分析显示,若持续血糖监测相比自我监测的新生儿重症监护病房入住相对风险低于1.15,则持续血糖监测更经济。

关键数值与推荐

  • 持续血糖监测每人成本26837美元 vs 自我监测每人成本29039美元,持续血糖监测较自我监测降低2202美元。
  • 持续血糖监测为最优策略的蒙特卡洛模拟比例为98.7%。
  • 持续血糖监测更经济的条件为新生儿重症监护病房入住相对风险低于1.15。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the United States, approximately 1% of pregnancies are complicated by pregestational diabetes. Individuals with type 1 diabetes have an increased risk of adverse maternal and neonatal outcomes. While continuous glucose monitoring has demonstrated benefits for patients with type 1 diabetes, its cost is higher than traditional intermittent fingerstick monitoring, particularly if used only during pregnancy. OBJECTIVE: To develop an economic analysis model to compare in silico the cost of continuous glucose monitoring and self-monitoring of blood glucose in a cohort of pregnant individuals with type 1 diabetes mellitus. STUDY DESIGN: We developed an economic analysis model to compare two glucose monitoring strategies in pregnant individuals with type 1 diabetes: continuous glucose monitoring and self-monitoring. The model considered hypertensive disorders of pregnancy, large for gestational age, cesarean delivery, neonatal intensive care unit (NICU) admission, and neonatal hypoglycemia. The primary outcome was the total cost per strategy in 2022 USD from a health system perspective, with self-monitoring as the reference group. Probabilities, relative risks, and costs were extracted from the literature, and the costs were adjusted to 2022 US dollars. Sensitivity analyses were conducted by varying parameters based on the probability, relative risk, and cost distributions. The robustness of the results was tested through 1000 Monte Carlo simulations. RESULTS: In the base-case analysis, the cost of pregnancy using continuous glucose monitoring was $26,837 compared to $29,039 for self-monitoring, resulting in a cost reduction of $2,202 per individual. The parameters with the greatest effect on the incremental cost included the relative risk of NICU admission, cost of NICU admission, continuous glucose monitoring costs, and usual care costs. Monte Carlo simulations indicated that continuous glucose monitoring was the optimal strategy 98.7% of the time. One-way sensitivity analysis showed that continuous glucose monitoring was more economical if the relative risk of NICU admission with continuous glucose monitoring vs. self-monitoring was below 1.15. CONCLUSION: Compared to self-monitoring, continuous glucose monitoring is an economical strategy for pregnant individuals with type 1 diabetes mellitus.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Diab YH, Saade G, Kawakita T, et al. Continuous glucose monitoring vs. self-monitoring in pregnant individuals with type 1 diabetes: an economic analysis. Am J Obstet Gynecol MFM. 2024. PMID: 38908796. doi:10.1016/j.ajogmf.2024.101413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。